Analysis

Compass Therapeutics, Inc. (CMPX) Stock Analysis

Compass Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to CMPX.

websiteCMPX/analysis/CMPX

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to CMPX.

Stock profile

Ticker

CMPX

Asset type

Stock

Market cap

$363.8M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Compass Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • CMPX primary listing

Latest Compass Therapeutics, Inc. news

Compass Therapeutics to Participate in Upcoming June Investor Events

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-...

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-C...

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activi...

Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

As recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary...

Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focus...

Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold

Research sections

Valuation

Review valuation context for Compass Therapeutics, Inc..

Future growth

Review future growth context for Compass Therapeutics, Inc..

Past performance

Review past performance context for Compass Therapeutics, Inc..

Financial health

Review financial health context for Compass Therapeutics, Inc..

Dividend

Review dividend context for Compass Therapeutics, Inc..

Management

Review management context for Compass Therapeutics, Inc..

Ownership

Review ownership context for Compass Therapeutics, Inc..

Other information

Review other information context for Compass Therapeutics, Inc..

Community

Review community context for Compass Therapeutics, Inc..